Аctual aspects of migraines preventive pharmacotherapy
E. V. Gantsgorn,
A. V. Safronenko,
V. I. Polyakova,
R. M. Manvelyan,
B. G. Antonyan,
A. V. Nikolaenko,
A. A. Baloyan,
G. A. Bokhanov,
D. S. Nepokrytaya,
A. A. Ilyina https://doi.org/10.30629/2658-7947-2024-29-2-17-23
Abstract
Headaches are one of the most common causes of disability worldwide, with migraines coming to the fore. A new and promising preventive strategy to combat migraine is drugs from the group of monoclonal antibodies to calcitonin-a gene-related peptide. High efficacy, good tolerability, and the ability to increase patient compliance increase the interest of specialists in these drugs. A potentially significant reduction in the economic burden on society and healthcare also plays an important role as a significant impact on improving the quality of life of patients. Despite the prospects of using these drugs for the prevention of migraine headaches, not all aspects related to this have been fully considered and resolved to date.
About the Authors
E. V. Gantsgorn
Rostov State Medical University
Russian Federation
Russian Federation
Rostov-on-Don
A. V. Safronenko
Rostov State Medical University
Russian Federation
Russian Federation
Rostov-on-Don
V. I. Polyakova
Rostov State Medical University
Russian Federation
Russian Federation
Rostov-on-Don
R. M. Manvelyan
Rostov State Medical University
Russian Federation
Russian Federation
Rostov-on-Don
B. G. Antonyan
Rostov State Medical University
Russian Federation
Russian Federation
Rostov-on-Don
A. V. Nikolaenko
Rostov State Medical University
Russian Federation
Russian Federation
Rostov-on-Don
A. A. Baloyan
Rostov State Medical University
Russian Federation
Russian Federation
Rostov-on-Don
G. A. Bokhanov
Rostov State Medical University
Russian Federation
Russian Federation
Rostov-on-Don
D. S. Nepokrytaya
Rostov State Medical University
Russian Federation
Russian Federation
Rostov-on-Don
A. A. Ilyina
Rostov State Medical University
Russian Federation
Russian Federation
Rostov-on-Don
References
1. World Health Organization. Headache disorders. 2016. (In Russ.). URL: https://www.who.int/ru/news-room/fact-sheets/detail/headache-disorders
2. Clinical recommendations “Migraine”. 2021, Ministry of Health of the Russian Federation. (In Russ.). URL: https://cr.minzdrav.gov.ru/schema/295_2
3. Steiner T.J., Stovner L., Jensen R., Uluduz D., Katsarava Z. The burden: the global campaign against headache. Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. The Journal of Headache and Pain. 2020;137:21. https://doi.org/10.1186/s10194-020-01208-0
4. Global, regional and national incidence, prevalence and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545–1602. https://doi.org/10.1016/S0140-6736(16)31678-6
5. Kolbin A.S., Naprienko M.V., Artemenko A.R., Vilyum I.A., Latysheva N.V., Proskurin M.A., Balykina Yu.Y. Socio-economic burden of chronic migraine in Russia. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2018;(3):26–44. (In Russ.). https://doi.org/10.24411/2588-0519-2018-10049
6. Azimova Y.E., Amelin A.V., Alferova V.V., Artemenko A.R., Akhmadeeva L.R., Golovacheva V.A. et al. Clinical guidelines «Migraine». Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2022;122(1-3):4-36. (In Russ.). https://doi.org/10.17116/jnevro20221220134
7. Kondratieva N.S., Anuchina A.A., Kokaeva Z.G., Naumova E.A., Azimova J.E., Sergeev A.V. et al. Genetics of migraine. Medical Genetics. 2016;15(1):3–13. (In Russ.). URL: https://www.medgen-journal.ru/jour/article/view/86
8. Glembotskaya G.T., Kozub O.V. Farmakoekonomicheskaya otsenka «bremeni» migreni v Rossiiskoi Federatsii. Klinicheskaya Farmakologiya i Terapiya. 2013;22(2):83–86. (In Russ.). URL: https://www.elibrary.ru/item.asp?id=21229349
9. Sadokha K.A. Migraine: present and future. Meditsinskie novosti. 2020;2:32–38. (In Russ.). URL: https://cyberleninka.ru/article/n/migren-nastoyaschee-i-buduschee
10. Boldyreva YU.V., Lebedev I.A., Osanova P.S.. Molecular mechanisms of migraine. Modernization of science and education: modern realities, ways of improvement. Materials of the XXXIV All-Russian Scientific and Practical Conference (Modernizaciya nauki i obrazovaniya: sovremennye realii, puti sovershenstvovaniya. Materialy XXXIV Vserossijskoj nauchno-prakticheskoj konferencii. Rostov-on-Don, 2021:72–74. Publisher: VVM Publishing House LLC (St. Petersburg). (In Russ.). URL: https://elibrary.ru/download/elibrary_46424958_85348031.pdf
11. Hu X., Zhou Y., Zhao H., Peng C. Migraine and the risk of stroke: an updated meta-analysis of prospective cohort studies. Neurol Sci. 2017;38(1):33–40. https://doi.org/10.1007/s10072-016-2746-z
12. Tepper T.S., Rapoport A., Sheftell F. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch. Neurol. 2002;59(7):1084– 1088. https://doi.org/10.1001/archneur.59.7.1084
13. Yang Y.C., Liang C., Chang C., Yang C., Shih P., Yau Y. et al. Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Metaanalysis. JAMA Netw Open. 2021;4(10):e2128544. https://doi.org/10.1001/jamanetworkopen.2021.28544
14. Marmura M. Triggers, protectors, and predictors in episodic migraine. Curr Pain Headache Rep. 2018;22(12):81. https://doi.org/10.1007/s11916-018-0734-0
15. Shields S.K., Goadsby P. Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine? Brain. 2005;128:86–97. https://doi.org/10.1093/brain/awh298
16. Jackson J., Kuriyama A., Kuwatsuka Y., Nickoloff S., Storch D., Jackson W. et al. Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis. PLoS One. 2019;14(3):e0212785. https://doi.org/10.1371/journal.pone.0212785
17. Becker B.W. Botulinum Toxin in the Treatment of Headache. Toxins (Basel). 2020;12(12):803. https://doi.org/110.3390/toxins12120803
18. Silberstein S., Holland S., Freitag F., Dodick D.W., Argoff C., Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78(17):1337–1345. https://doi.org/10.1212/WNL.0b013e3182535d20
19. Sorokina N.D., Pertsov S.S., Selitsky G.V., Zherdeva A.S. Antiepileptic drugs in the treatment of migraine and neuropathic pain. Russian journal of pain. 2021;19(3):45–52. (In Russ.). https://doi.org/10.17116/pain20211903145
20. Schneider S.J., Patterson M., Jimenez X. Beyond depression: Other uses for tricyclic antidepressants. Cleve Clin. J. Med. 2019;86(12):807–814. https://doi.org/10.3949/ccjm.86a.19005
21. Azimova J.E., Ashikhmin Ya.I., Kukushkin M.L. Monoclonal antibodies to CGRP: a new word in the treatment of migraine. Russian Journal of Pain. 2019;17(2):61–66. (In Russ.). https://doi.org/10.25731/RASP.2019.02.22
22. Vandervorst V.F., Van Deun L., Van Dycke A., Paemeleire K., Reuter U., Schoenen J., Versijpt J. CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. The journal of headache and pain. 2021;22(1):128. https://doi.org/10.1186/s10194-021-01335-2
23. Dodick D., Doty E., Aurora S., Ruff D., Stauffer V., Jedynak J. et al. Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine. Cephalalgia. 2021;41(3):340–352. https://doi.org/10.1177/0333102420966658
24. Goadsby G.P., Reuter U., Hallström Y., Broessner G., Bonner J.H., Zhang F. et al. A controlled trial of erenumab for episodic migraine. N. Engl. J. Med. 2017;377(22):2123–2132. https://doi.org/10.1056/NEJMoa1705848
25. Ekusheva E.V., Artemenko A.R., Shirshova E.V., Sokov P.E., Plieva A.M. The use of the monoclonal antibody Erenumab in patients with chronic migraine in real clinical experience. Russian Neurological Journal (Rossijskij Nevrologicheskiy Zhurnal). 2021;26(5):44–50. (In Russ.). https://doi.org/10.30629/2658-7947-2021-26-5-44-50
26. Saper S.J., Lipton R., Kudrow D., Hirman J., Dodick D., Silberstein S. et al. A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of eptinezumab in frequent episodic migraine prevention: primary results of the PROMISE 1 (PRevention Of Migraine via Intravenous eptinezumab: Safety and Efficacy 1) Trial. Cephalalgia. 2017;37:33. https://scholar.google.com/citations?view_op=view_citation&hl=en&user=ymK9SakAAAAJ&citation_for_view=ymK9SakAAAAJ:YOwf2qJgpHMC
27. Dodick D.W., Silberstein S.D., Bigal M.E., Yeung P.P., Goadsby P.J., Blankenbiller T. et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine. JAMA. 2018;319(19):1999–2008. https://doi.org/10.1001/jama.2018.4853
28. Lampl L.C., MaassenVanDenBrink A., Deligianni C., Gil-Gouveia R., Jassal T., Sanchez-Del-Rio M. et al. The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J. Headache Pain. 2023;24(1):56. https://doi.org/10.1186/s10194-023-01594-1
29. Safronenko A.V., Gantsgorn E.V., Postnikova E.S., Polyakova V.I., Manvelyan R.M., Antonyan B.G. et al. Usage of fremanezumab for the prevention of exacerbations of chronic migraine: clinical case. Experimental and clinical pharmacology. 2023;86(8):9–14. (In Russ.). https://doi.org/10.30906/0869-2092-2023-86-8-9-14
30. Camporeale A., Kudrow D., Sides R., Wang S., Dycke A.V., Selzler K.J., Stauffer V.L. A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine. BMC Neurology. 2018;188(18). https://doi.org/10.1186/s12883-018-1193-2
31. Sacco S., Amin F., Ashin M., Bendtsen L., Deligianni C.I., Gil-Gouveia R. et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention — 2022 update. J. Headache Pain. 2022;23:67. https://doi.org/10.1186/s10194-022-01431-x
32. Dodick D., Lipton R., Silberstein S., Goadsby P., Biondi D., Hirman J. et al. Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. Cephalalgia. 2019;39(9):1075– 1085. https://doi.org/10.1177/0333102419858355
33. Detke H.C., Goadsby P.J., Wang S., Friedman D.I., Selzler K.J., Aurora S.K. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211–e2221. https://doi.org/10.1212/WNL.0000000000006640
34. Silberstein S., Dodick D., Bigal M., Yeung P.P, Goadsby P.J, Blankenbiller T. et al. Fremanezumab for the preventive treatment of chronic migraine. N. Engl. J. Med. 2017;377:2113–2122. https://doi.org/10.1056/NEJMoa1709038
35. Diener H.C., Marmura M.J., Tepper S.J., Cowan R., Starling A.J., Diamond M.L. et al. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2. Headache. 2021;61(1):125–136. https://doi.org/10.1111/head.14036
36. Silberstein S., Cohen J., Seminerio M., Yang R., Ashina S., Katsarava Z. The impact of fremanezumab on medication over-use in patients with chronic migraine: subgroup analysis of the HALO CM study. J. Headache Pain. 2020;21(1):114. https://doi.org/10.1186/s10194-020-01173-8
37. Sprenger S.T., Viana M., Tassorelli C. Current prophylactic medications for migraine and their potential mechanisms of action. Neurotherapeutics. 2018;15:313–323. https://doi.org/10.1007/s13311-018-0621-8
38. Pham P.A., Burch R. Headache. 2020;60:4–5. https://headache-journal.onlinelibrary.wiley.com/toc/15264610/2020/60/5
39. Ornello O.R., Baraldi C., Guerzoni S., Lambru G., Andreou A.P., Raffaelli B. et al. Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study. J. Headache Pain. 2022;23(1):38. https://doi.org/10.1186/s10194-022-01408-w
40. Sacco S., Lampl C., MaassenVanDenBrink A., Caponnetto V., Braschinsky M., Ducros A. et al. Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance. J. Headache Pain. 2021;22(1):39. https://doi.org/10.1186/s10194-021-01252-4
41. Restituto R.D., Fabo E., Bujanda M. Salvage therapy for patients who do not respond to the first anti-CGRP monoclonal antibody: a new chance for patients with migraine? Neurology Perspectives. 2022;2(2):102–104. https://doi.org/10.1016/j.neurop.2021.11.009
42. Argyriou A.A., Dermitzakis E.V., Xiromerisiou G., Vikelis M. On a botulinum toxin A add-on to monoclonal anti-CGRP antibodies in treatment-refractory chronic migraine. Toxins. 2022;14(12):847. https://doi.org/10.3390/toxins14120847
43. Goadsby G.P., Silberstein S., Yeung P., Cohen J.M., Ning X., Yang R., Dodick D.W. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study. Neurology. 2020;95(18):e2487-e2499. https://doi.org/10.1212/WNL.0000000000010600
44. Depre C., Antalik L., Starling A., Koren M., Eisele O., Lenz R.A., Mikol D.D. A randomized, double-blind, placebo-controlled study to evaluate the effect of erenumab on exercise time during a treadmill test in patients with stable angina. Headache. 2018;58(5):715-723. https://doi.org/10.1111/head.13316
45. Bussiere J., Davies R., Dean C., Xu C., Kim K.H., Vargas H.M. et al. Nonclinical safety evaluation of erenumab, a GGRP receptor for the prevention of migraine. Regulatory Toxicology and Pharmacology. 2019;106:224–238. https://doi.org/10.1016/j.yrtph.2019.05.013
46. Yadav S., Yadav Y.S., Goel M.M., Singh U., Natu S.M., Singh Negi M.P. Calcitonin gene- and parathyroid hormone-related peptides in normotensive and preeclamptic pregnancies: a nested case–control study. Arch Gynecol Obstet. 2014;290(5):897–903. https://doi.org/10.1007/s00404-014-3303-8
47. Al-Hassany L., Goadsby P.J., Danser A.J., Maassen Van Den Brank A. С. Lancet Neurol. 2022;21(3):284–294. https://doi.org/10.1016/S1474-4422(21)00409-9
Review
For citations:
Gantsgorn E.V., Safronenko A.V., Polyakova V.I., Manvelyan R.M., Antonyan B.G., Nikolaenko A.V., Baloyan A.A., Bokhanov G.A., Nepokrytaya D.S., Ilyina A.A. Аctual aspects of migraines preventive pharmacotherapy. Russian neurological journal. 2024;29(2):17-23. (In Russ.) https://doi.org/10.30629/2658-7947-2024-29-2-17-23
Views:
458
Email this article 